Phoenix Biotech Acquisition Stock Price, News & Analysis

PBAXU NASDAQ

Company Description

Phoenix Biotech Acquisition (NASDAQ: PBAXU) is a publicly traded company.

PBAXU stock has declined 100.0% over the past year.

This page provides a comprehensive overview of PBAXU stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart

$—

0.00%

0.00

Last updated:

-100%

Performance 1 year

$0.0

Market Cap

6.2M

Shares outstanding

Phoenix Biotech Acquisition (PBAXU) stock. Over the past 12 months, the stock has lost 100.0%.

Latest News

View All

November 22, 2021

+0.69%

Phoenix Biotech Acquisition Corp. Class A Common Shares and Warrants to Commence Trading Separately on November 26, 2021

acquisition

October 8, 2021

+0.35%

Phoenix Biotech Acquisition Corp. Announces Completion of $175,000,000 Initial Public Offering, Including Exercise of Over-Allotment Option

IPO offering acquisition

October 5, 2021

—

Phoenix Biotech Acquisition Corp. Announces Pricing of $155,000,000 Initial Public Offering

IPO offering acquisition

Phoenix Biotech Acquisition has 3 recent news articles. Of the recent coverage, 2 articles coincided with positive price movement and 0 with negative movement. Key topics include acquisition, IPO, offering. View all PBAXU news →

SEC Filings

View All

No SEC filings available for PBAXU.

Financial Highlights

View Full Financials

—

Revenue (TTM)

—

Net Income (TTM)

—

Diluted EPS (TTM)

—

Operating Cash Flow

—

Net Profit Margin

—

Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months